AIDS reviews · 2005
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop.
Consensus StatementСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Carosi Giampiero, Puoti Massimo, Antonucci Giovanni, De Luca Andrea, Maserati Renato, Torti Carlo, Bonfanti Paolo, Bonora Stefano, Bruno Raffaele, Gaeta Giovanni Battista, Antinori Andrea, Monforte Antonella d'Arminio, Orani Anna, Sagnelli Evangelista, Cargnel Antonietta, Cauda Roberto, Mazzotta Francesco, Pastore Giuseppe, Suter Fredy, Vullo Vincenzo, Italian ART, HCV-HIV Coinfection Working Group
Аннотация
Hepatitis C virus common transmission routes and HCV coinfection is frequent in persons living with HIV. Liver enzyme elevation following the initiation of antiretroviral therapy is frequently seen in HIV-infected patients with chronic liver disease, particularly those with chronic hepatitis C. This complication may lead to treatment discontinuation, complicating HIV therapeutic management. Multiple factors influence the risk of liver toxicity under antiretroviral therapy, including the specific drug in use (e.g. use of full doses of ritonavir), and environmental factors (e.g. alcohol abuse). However a beneficial effect of antiretroviral therapy on liver disease has been supported by some studies. Despite increasing knowledge of HCV/HIV coinfection, there is no clear consensus on how to treat HIV in HCV-coinfected patients An Italian group of experts were invited to discuss in detail the current risks and implications of antiretroviral treatment in HIV-infected persons with chronic hepatitis C, and their main conclusions are summarized in this consensus document.